Found 8 clinical trials
Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma
This trial aimed to investigate the therapeutic efficacy of daratumumnab plus chemitherapy in multiple myeloma with plasmacytoma.
- 0 views
- 23 Jan, 2021
- 1 location
Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors
This study is a multi-center, non-randomized, single-arm, open clinical trial.
- 0 views
- 27 Jan, 2021
- 1 location
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
The purpose of this study is to investigate if the combination of CC-486 with lenalidomide and radiation therapy is a safe and effective treatment for plasmacytoma.
- 0 views
- 26 Jan, 2021
- 7 locations
Ixazomib Citrate Lenalidomide and Dexamethasone in Treating Patients With POEMS Syndrome
This phase II trial studies how well ixazomib citrate, lenalidomide, and dexamethasone work in treating patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, …
- 1 views
- 23 Mar, 2021
- 2 locations
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back (relapsed) or has not responded to previous treatment (refractory). KRT-232 (AMG 232) may stop the growth of …
- 27 views
- 15 May, 2021
- 4 locations
Panobinostat Gemcitabine Hydrochloride Busulfan and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
This phase II trial studies how well panobinostat, gemcitabine hydrochloride, busulfan, and melphalan before stem cell transplant work in treating patients with multiple myeloma that does not respond to treatment (refractory) or has returned (relapsed). Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed …
- 0 views
- 23 Jan, 2021
- 1 location
Daratumumab Combined With Bortezomib Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease
This trial will try to establish the feasibility and efficacy of the combination of DaraVCD in Multiple Myeloma (MM) patients presenting with extramedullary disease (EMD). The study will be conducted as a Phase II trial. Forty patients will be included in the study cohort. All patients will be followed closely …
- 3 views
- 10 Feb, 2021
- 8 locations
A Phase 1 Study of Ruxolitinib Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
- 36 views
- 24 Jan, 2021
- 10 locations